Global Malaria Vaccines Market Size By Type (Pre-Erythrocytic Vaccine, Erythrocytic Vaccine), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Malaria Vaccines Market was valued at USD 270 million in 2023 and is projected to reach USD 890 million by 2031, growing at a CAGR of 16.2% during the forecast period from 2023 to 2031. This growth is fueled by increasing global efforts to eliminate malaria, rising government and international funding, and the rollout of WHO-recommended malaria vaccines such as RTS,S/AS01 (Mosquirix). Additionally, expanding clinical research and growing awareness about malaria prevention in endemic regions are supporting market acceleration.

Drivers:

1. Rising Malaria Burden in Endemic Regions:

Sub-Saharan Africa and parts of Asia continue to experience high malaria incidence, driving urgent demand for effective preventive solutions like vaccines. The increased incidence rate is a strong motivator for governments and NGOs to adopt immunization strategies.

2. Strong International Support and Funding:

Organizations such as GAVI, WHO, and the Gates Foundation have significantly increased funding for malaria vaccine development and distribution, enabling large-scale immunization programs in low- and middle-income countries.

3. Advancement in Vaccine Technologies:

Innovations such as recombinant protein vaccines, viral vector platforms, and next-generation multi-antigen vaccines are expected to expand the range and efficacy of available malaria vaccines, enhancing market prospects.

Restraints:

1. High Cost of Development and Limited Access:

Vaccine development for malaria is complex and costly, with substantial funding required for R&D, trials, and cold chain logistics. Access in remote or underserved regions also poses logistical challenges.

2. Vaccine Hesitancy and Limited Awareness:

In many malaria-endemic areas, public trust in vaccines can be limited, and lack of awareness about vaccine availability can hinder adoption, especially among rural populations.

Opportunity:

1. Expansion in Asia-Pacific and Latin America:

These regions are emerging as critical growth areas due to rising cases and proactive government vaccination campaigns. Market players can tap into these regions with partnerships and subsidized vaccine programs.

2. Development of Multivalent and Transmission-Blocking Vaccines:

New R&D targeting transmission-blocking and multivalent vaccines presents a key opportunity. These can potentially prevent parasite spread from one individual to another, playing a vital role in eradication strategies.

Market by System Type Insights:

Based on vaccine platform, the Recombinant Protein-based Vaccines segment dominated the market in 2023, driven by the widespread adoption of RTS,S/AS01. However, the Viral Vector-based Vaccines segment is expected to witness the highest CAGR during the forecast period due to pipeline candidates demonstrating superior immunogenicity in early trials.

Market by End-use Insights:

The Public Health Institutions segment accounted for the largest revenue share in 2023, owing to large-scale procurement and distribution by government and international health agencies. The Private Healthcare Providers segment is expected to grow steadily, particularly in urban centers of developing countries where private vaccination is gaining momentum.

Market by Regional Insights:

Africa led the global malaria vaccines market in 2023, supported by a high disease burden and strong international funding. Asia-Pacific is projected to exhibit the highest growth through 2031, driven by malaria resurgence in Southeast Asia and government-led mass immunization efforts. Latin America also presents emerging opportunities as nations prioritize tropical disease control programs.

Competitive Scenario:

Key players in the global malaria vaccines market include:

GlaxoSmithKline plc

Bharat Biotech International Ltd.

BioNTech SE

Sanaria Inc.

Moderna, Inc.

Novavax, Inc.

Oxford University (Jenner Institute)

Serum Institute of India

These companies are engaged in strategic partnerships, collaborative research, and new product development. For instance:

In 2023, GSK announced expanded manufacturing capabilities for Mosquirix to meet demand in African countries.

Bharat Biotech launched Phase II trials for its transmission-blocking malaria vaccine candidate in India and Africa.

In 2024, BioNTech partnered with the WHO to accelerate mRNA malaria vaccine deployment across sub-Saharan Africa.

Scope of Work – Global Malaria Vaccines Market

Key Market Developments:

November 2023: WHO approved broader use of RTS,S/AS01 vaccine across high-burden African nations.

February 2024: BioNTech initiated clinical trials of its mRNA-based malaria vaccine in Kenya and Rwanda.

April 2025: Gavi, the Vaccine Alliance, pledged an additional USD 400 million in funding to scale up malaria vaccine distribution globally.

FAQs:

1) What is the current market size of the Global Malaria Vaccines Market?

The market size was valued at USD 270 million in 2023.

2) What is the major growth driver of the Global Malaria Vaccines Market?

The primary driver is the rising global malaria burden and increasing international funding for vaccine programs.

3) Which is the largest region during the forecast period in the Global Malaria Vaccines Market?

Africa is expected to remain the largest region due to its high malaria incidence.

4) Which segment accounted for the largest market share in the Global Malaria Vaccines Market?

The Recombinant Protein-based Vaccines segment held the largest share in 2023.

5) Who are the key market players in the Global Malaria Vaccines Market?

Key players include GlaxoSmithKline, Bharat Biotech, BioNTech, Sanaria, and Moderna.